Current progress in bionanomaterials to modulate the epigenome.


Journal

Biomaterials science
ISSN: 2047-4849
Titre abrégé: Biomater Sci
Pays: England
ID NLM: 101593571

Informations de publication

Date de publication:
13 Sep 2022
Historique:
pubmed: 27 7 2022
medline: 15 9 2022
entrez: 26 7 2022
Statut: epublish

Résumé

Recent advances in genomics during the 1990s have made it possible to study and identify genetic and epigenetic responses of cells and tissues to various drugs and environmental factors. This has accelerated the number of targets available to treat a range of diseases from cancer to wound healing disorders. Equally interesting is the understanding of how bio- and nanomaterials alter gene expression through epigenetic mechanisms, and whether they have the potential to elicit a positive therapeutic response without requiring additional biomolecule delivery. In fact, from a cell's perspective, a biomaterial is nothing more than an environmental factor, and so it has the power to epigenetically modulate gene expression of cells in contact with it. Understanding these epigenetic interactions between biomaterials and cells will open new avenues in the development of technologies that can not only provide biological signals (

Identifiants

pubmed: 35880652
doi: 10.1039/d2bm01027e
doi:

Substances chimiques

Biocompatible Materials 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

5081-5091

Auteurs

Anna D Y Rhodes (ADY)

Department of Bioengineering, Imperial College London, London W12 0BZ, UK. n.oliva-jorge@imperial.ac.uk.

Jose Antonio Duran-Mota (JA)

Department of Bioengineering, Imperial College London, London W12 0BZ, UK. n.oliva-jorge@imperial.ac.uk.
Materials Engineering Group (GEMAT), IQS Barcelona, Barcelona 08017, Spain.

Nuria Oliva (N)

Department of Bioengineering, Imperial College London, London W12 0BZ, UK. n.oliva-jorge@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH